Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Merck
Teva
Moodys
Queensland Health
Johnson and Johnson
Argus Health
Baxter
Citi

Generated: November 15, 2018

DrugPatentWatch Database Preview

Choriogonadotropin alfa - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for choriogonadotropin alfa and what is the scope of choriogonadotropin alfa patent protection?

Choriogonadotropin alfa is the generic ingredient in one branded drug marketed by Emd Serono and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for choriogonadotropin alfa
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: 1
Clinical Trials: 4
DailyMed Link:choriogonadotropin alfa at DailyMed
Pharmacology for choriogonadotropin alfa
Ingredient-typeGonadotropins
Drug ClassGonadotropin

US Patents and Regulatory Information for choriogonadotropin alfa

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for choriogonadotropin alfa

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;INJECTION 021149-001 Sep 20, 2000 ➤ Try a Free Trial ➤ Try a Free Trial
Emd Serono OVIDREL choriogonadotropin alfa INJECTABLE;SUBCUTANEOUS 021149-002 Oct 6, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

International Patents for choriogonadotropin alfa

Country Document Number Estimated Expiration
Ukraine 61053 ➤ Try a Free Trial
Brazil 9510567 ➤ Try a Free Trial
Hong Kong 1006365 ➤ Try a Free Trial
Portugal 814841 ➤ Try a Free Trial
Spain 2166841 ➤ Try a Free Trial
Denmark 0814841 ➤ Try a Free Trial
European Patent Office 0814841 ➤ Try a Free Trial
Country Document Number Estimated Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Supplementary Protection Certificates for choriogonadotropin alfa

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB01/030 United Kingdom ➤ Try a Free Trial PRODUCT NAME: RECOMBINANT CHORIOGONADOTROPIN ALFA; REGISTERED: UK EU/1/00/165/001-006 20010202
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Merck
Teva
Moodys
Queensland Health
Johnson and Johnson
Argus Health
Baxter
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.